Exagen XGN 深 沪
交易中 07-09 11:53:06 美东时间
4.50
+0.140
+3.21%
华盛通- 最 高4.53
- 今 开4.37
- 成交量 2.35万股
- 最 低 4.355
- 昨 收 4.36
- 总市值 1.09亿
- 52周最高 12.23
- 市盈率 静 --
- 换手率 0.10%
- 52周最低 2.59
- 委 比 90.99%
- 总股本 2415.98万
- 历史最高 29.858
- 量 比 0.32
- 振 幅 4.01%
- 历史最低 1.3003
- 每 手 1
- 风险率 2.94%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | 潜在涨幅135.66%！Ocular Therapeutix获Chardan Capital升目标价至23美元，维持"买入"评级
今日重点评级关注：Chardan Capital：维持Ocular Therapeutix"买入"评级，目标价从21美元升至23美元；Guggenheim：维持Amylyx Pharmaceuticals"买入"评级，目标价从30美元升至40美元
06-26 17:42
Roth Capital Initiates Coverage On Exagen with Buy Rating, Announces Price Target of $8
Roth Capital analyst Max Masucci initiates coverage on Exagen (NASDAQ:XGN) with a Buy rating and announces Price Target of $8.
06-25 18:28
Nuwellis prices $6M public offering
Nuwellis, Inc. (Nasdaq: NUWE) on Friday said it priced a public offering expected to raise approximately $6 million in gross proceeds. The offering consists of 20 million shares of common stock, or pr...
06-05 20:54
Exagen Announces Publication Of New Systematic Review Demonstrating That AVISE Lupus Algorithm Delivers Superior Diagnostic Accuracy And Consistency Across Patient Populations Compared With Conventional Serologic Tests Alone
Uniquely identified ~25% of the SLE patients who would otherwise be missed by conventional markersDemonstrated superior diagnostic accuracy compared with conventional testing, supporting earlier, more definitive
06-01 21:03
Exagen Announces Publication of Systematic Review Confirming Robust Real-World Performance of AVISE Lupus
Exagen Inc. announced that its AVISE Lupus algorithm demonstrates superior diagnostic accuracy for Systemic Lupus Erythematosus (SLE), identifying 25% of patients missed by conventional markers. The algorithm consistently performed across 1,200 SLE patients and 14 medical centers, with high specificity and sensitivity. This advancement supports earlier diagnosis, preventing organ damage and improving outcomes. Exagen's CEO highlighted the algorit...
06-01 13:00
电话会总结 ｜ Exagen(XGN)2026财年Q1业绩电话会核心要点
<span style="color:#999999;">编者按：聚焦公司高管观点与展望，深挖业绩背后的信息，助力投资者把握先机。</span><blockquote><p><span style="color:#fa1432;"><strong>业绩回顾</strong></span></p></blockquote><p>• 根据Exagen业绩会实录，以下是财务业绩回顾摘要： ## 1. 财务业绩 **营收表现：** 2026年第一季度营收达到1,730万美元，同比增长12%，创下公司历史上最高的第一季度营收纪录。 **盈利能力：** 毛利率为59%，与去年同期持平，但较2025年第四季度环比上升360个基点。调整后EBITDA亏损220万美元，较去年同期改善14%。 **现金状况：** 季度末现金、现金等价物及受限现金余额接近2,200万美元，超出内部预期。 **运营费用：** 总运营费用为1,360万美元，同比增长9%。其中销售、一般及管理费用(SG&A)为1,20
05-13 12:21
美股大行评级 | 富国银行上调英伟达目标价从265美元升至315美元；Alamar、AEVEX获多家大行首予“买入”评级
今日重点评级关注：Needham：维持Artiva Biotherapeutics"买入"评级，目标价从18美元升至41美元；HC Wainwright & Co.：维持SAB Biotherapeutics"买入"评级，目标价从7美元升至10美元
05-13 11:46
BTIG Maintains Buy on Exagen, Lowers Price Target to $8
BTIG analyst Mark Massaro maintains Exagen (NASDAQ:XGN) with a Buy and lowers the price target from $9 to $8.
05-12 18:49
Exagen shares are trading higher after the company reported better-than-expected Q1 financial results and reaffirmed its FY2026 sales guidance.
Exagen shares are trading higher after the company reported better-than-expecte...
05-12 00:14
